Mass Spectrometry Facility; Department of sBiochemistry and Molecular Pharmacology
Fluids and Secretions | Hemic and Immune Systems | Investigative Techniques | Laboratory and Basic Science Research | Pharmaceutical Preparations
BACKGROUND AND OBJECTIVE: Based on previous experience of sorbent-mediated ticagrelor, dabigatran, and radiocontrast agent removal, we set out in this study to test the effect of two sorbents on the removal of edoxaban, a factor Xa antagonist direct oral anticoagulant.
METHODS: We circulated 100 mL of edoxaban solution during six first-pass cycles through 40-mL sorbent columns (containing either CytoSorb in three passes or Porapak Q 50-80 mesh in the remaining three passes) during experiments using human plasma and 4% bovine serum albumin solution as drug vehicles. Drug concentration was measured by liquid chromatography-tandem mass spectrometry.
RESULTS: Edoxaban concentration in two experiments performed with human plasma dropped from 276.8 to 2.7 ng/mL and undetectable concentrations, respectively, with CytoSorb or Porapak Q 50-80 mesh (p = 0.0031). The average edoxaban concentration decreased from 407 ng/mL +/- 216 ng/mL to 3.3 ng/mL +/- 7 ng/mL (p = 0.017), for a removal rate of 99% across all six samples of human plasma (two samples) and bovine serum albumin solution (four samples). In four out of the six adsorbed samples, the drug concentrations were undetectable.
CONCLUSION: Sorbent-mediated technology may represent a viable pathway for edoxaban removal from human plasma or albumin solution.
Porapak Q 50–80 mesh, CytoSorb, sorbents, edoxaban, plasma, albumin
Rights and Permissions
Copyright © The Author(s) 2020. Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
DOI of Published Version
Angheloiu AA, Tan Y, Ruse C, Shaffer SA, Angheloiu GO. In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution. Drugs R D. 2020 Sep;20(3):217-223. doi: 10.1007/s40268-020-00308-1. PMID: 32415538; PMCID: PMC7419416. Link to article on publisher's site
Drugs in R and D
Angheloiu AA, Tan Y, Ruse C, Shaffer SA, Angheloiu GO. (2020). In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution. Open Access Articles. https://doi.org/10.1007/s40268-020-00308-1. Retrieved from https://escholarship.umassmed.edu/oapubs/4354
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License